assessing the efficacy of intraventricular recombinant tissue-type plasminogen activator (rtPA) for spontaneous intraventricular hemorrhage (IVH). This subanalysis assesses the effect of dose of rtPA by region on clearance of IVH. Methods-Sixty-four patients within 12 to 24 hours of spontaneous IVH were randomized to placebo or 0.3 mg, 1 mg, or 3 mg of rtPA twice daily through an extraventricular drain. Twelve subregions of the ventricles were scored from 0 to 4. Effect of dose on IVH clearance to 50% of baseline score was compared by survival analysis for all regions combined and by subregion. Models including ventricular region, dose, and baseline score were compared by Cox proportional hazards. Key Words: intraventricular hemorrhage Ⅲ randomized controlled trials Ⅲ thrombolysis I ntraventricular hemorrhage (IVH) complicates 40% of intracerebral hemorrhage 1 and increases mortality 2 due to larger associated intracerebral hemorrhage and occlusion of the third and fourth ventricles. However, normalization of intracranial pressure does not reverse the neurological deficit, 3 probably because of direct toxicity of blood products. 4 Recombinant tissue-type plasminogen activator (rtPA) increases resolution of IVH, 5-8 reducing intracranial pressure, duration of cerebrospinal fluid diversion, and direct neural injury. The clinical efficacy of rtPA is being assessed in the The Clot Lysis: Evaluating Accelerated Resolution (CLEAR) III trial. This analysis of the safety 8 and dose-finding phases of the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) program assesses the effect of rtPA dose according to ventricular region (online-only Supplemental Data).
I ntraventricular hemorrhage (IVH) complicates 40% of intracerebral hemorrhage 1 and increases mortality 2 due to larger associated intracerebral hemorrhage and occlusion of the third and fourth ventricles. However, normalization of intracranial pressure does not reverse the neurological deficit, 3 probably because of direct toxicity of blood products. 4 Recombinant tissue-type plasminogen activator (rtPA) increases resolution of IVH, [5] [6] [7] [8] reducing intracranial pressure, duration of cerebrospinal fluid diversion, and direct neural injury. The clinical efficacy of rtPA is being assessed in the The Clot Lysis: Evaluating Accelerated Resolution (CLEAR) III trial. This analysis of the safety 8 and dose-finding phases of the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) program assesses the effect of rtPA dose according to ventricular region (online-only Supplemental Data).
Methods
CLEAR-IVH safety recruited 48 patients aged 18 to 75 years old, who had at least 1 CT scan after insertion of an extraventricular drain (EVD) and started treatment within 12 to 24 hours of a spontaneous IVH. 8 They received 3 mg intraventricular rtPA or placebo twice daily, after which the EVD was clamped for 1 hour. Patients underwent daily CT scans until treatment was completed and a follow-up scan between 28 and 32 days. In CLEAR-IVH dosefinding Phase 1, 16 patients were randomized to 0.3 mg or 1 mg rtPA according to the same protocol. The second phase of this study was excluded due to a different dosing schedule.
The modified Graeb scale 9 divided the lateral ventricles into anterior (anterolateral) and posterior halves (posterolateral), the third ventricle into anterior and posterior halves, and the fourth ventricle into superior and inferior halves (Supplemental Figure III) . "Ipsilateral" or "contralateral" ventricles were defined relative to catheterassociated rtPA administration, because the impact of IVH and intracerebral hemorrhage laterality has been reported elsewhere. 10 A.J.S.W., S.M., and N.L.U. independently scored CLEAR-IVH safety scans, whereas CLEAR-IVH dose-finding scans were scored by A.J.S.W. and D.F.H. "Stability" CT was the first scan with no catheter-tract hemorrhage or intracerebral hemorrhage growth Ͼ5 mL. Interindividual agreement was assessed by statistics. Change in total score across all regions compared with the stability CT was correlated with change in IVH volume measured by computerassisted volumetrics.
Reduction in score to 90%, 75%, 50%, or 25% of the stability CT (t 90 , t 75 , t 50 , t 25 ) was compared between regions and dose by Kaplan-Meier survival analysis (log-rank test). Effect of baseline score, ventricular region, and drug dose was modeled by Cox proportional hazards with and without an interaction term between dose and region. Sensitivity analyses excluded patients who were censored within 7 days or excluded the placebo group.
Results
Patient characteristics have been reported previously. 8 
Discussion
IVH cleared quickest in the midline ventricles, even with placebo, probably due to a higher turnover of cerebrospinal fluid. This regional difference was greater with rtPA, probably due to greater drug exposure with greater proximity of IVH to the EVD. Once the midline ventricles were open, rtPA is diverted away from the posterolateral ventricles, potentially limiting the effectiveness of intraventricular rtPA in regions distant to the EVD. This development of the Graeb score 9 assesses ventricular obstruction by region, does not overweight the midline ventricles, is simple to perform, and is strongly correlated with changes in blood volume. However, the dose-effect in the midline ventricles was not seen in another study looking at dose of intraventricular fibrinolysis, 11 although this nonrandomized study only compared 2 doses of rtPA with a 
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poorer temporal resolution of CT scans. This analysis only assessed the regional dose-dependence of IVH clearance because the safety aspects of intraventricular rtPA have already been reported, 8 but it provides a method for analyzing the region-dependent effect of rtPA on clinical outcomes in future trials such as CLEAR III. However, future studies will be needed to address dose-safety and whether distribution or severity of IVH should determine EVD location or rtPA dose.
In conclusion, rtPA administered through an EVD increases resolution of IVH in a dose-dependent fashion and has a greater effect on the midline ventricles and anterolateral sections of the lateral ventricles than the posterolateral ventricles. It is likely to increase the rate of resolution of obstructive hydrocephalus but has a less significant effect on blood in the posterolateral ventricles. 
